[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"da2147db-6d4b-4bfe-ac5e-f6786f79f209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881265","created_at":"2023-05-31T15:05:36.513Z","updated_at":"2025-02-25T14:17:59.340Z","phase":"Phase 2","brief_title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT05881265","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-18"},{"id":"e5e2b950-7554-4958-b2db-713f66c51761","acronym":"","url":"https://clinicaltrials.gov/study/NCT03280030","created_at":"2021-01-18T16:11:51.281Z","updated_at":"2025-02-25T15:42:59.213Z","phase":"Phase 2","brief_title":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","source_id_and_acronym":"NCT03280030","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/06/2018","start_date":" 04/06/2018","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 11/14/2022","study_completion_date":" 11/14/2022","last_update_posted":"2025-02-11"},{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"e3f709a4-4377-4abd-8838-8424d0acce76","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983824","created_at":"2021-01-18T19:35:36.667Z","updated_at":"2024-07-02T16:34:59.061Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03983824","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RARA • PML • CD4","pipe":"","alterations":" ","tags":["RARA • PML • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • mitoxantrone • peposertib (M3814) • Starasid (cytarabine ocfosfate)"],"overall_status":"Suspended","enrollment":" Enrollment 48","initiation":"Initiation: 05/05/2020","start_date":" 05/05/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"5c7bafb8-a49c-4d34-97a5-3ed538c792ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832320","created_at":"2023-04-27T14:04:55.563Z","updated_at":"2024-07-02T16:35:04.431Z","phase":"","brief_title":"Optimum Induction Therapy of Low-risk APL","source_id_and_acronym":"NCT05832320","lead_sponsor":"Peking University People's Hospital","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"eae87f81-b151-4534-856f-6fe520d9c93c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04793919","created_at":"2024-04-15T17:24:45.119Z","updated_at":"2024-07-02T16:35:09.764Z","phase":"Phase 2","brief_title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT04793919","lead_sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 10/09/2025","primary_completion_date":" 10/09/2025","study_txt":" Completion: 10/10/2027","study_completion_date":" 10/10/2027","last_update_posted":"2024-04-15"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"192b121c-dfa2-4eff-ae2b-d136c65ef93b","acronym":" UNIFY","url":"https://clinicaltrials.gov/study/NCT03512197","created_at":"2021-01-18T17:17:13.296Z","updated_at":"2024-07-02T16:35:39.473Z","phase":"Phase 3","brief_title":"A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT03512197 -  UNIFY","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 D835 • FLT3 I836","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 511","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 02/12/2021","primary_completion_date":" 02/12/2021","study_txt":" Completion: 02/12/2021","study_completion_date":" 02/12/2021","last_update_posted":"2023-08-21"},{"id":"a33ded0a-8d2b-4dec-8eb6-bc89ee154d4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01420926","created_at":"2021-01-18T05:51:36.898Z","updated_at":"2024-07-02T16:35:54.587Z","phase":"Phase 2","brief_title":"Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01420926","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • RUNX1 • PML","pipe":" | ","alterations":" FLT3 mutation • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["FLT3 • RUNX1 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • azacitidine • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 11/16/2011","start_date":" 11/16/2011","primary_txt":" Primary completion: 06/05/2016","primary_completion_date":" 06/05/2016","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2023-02-28"},{"id":"524a0eb6-071e-4968-ae8c-51db52817873","acronym":"","url":"https://clinicaltrials.gov/study/NCT00492856","created_at":"2021-01-18T01:45:43.940Z","updated_at":"2024-07-02T16:35:57.935Z","phase":"Phase 3","brief_title":"S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT00492856","lead_sponsor":"Southwest Oncology Group","biomarkers":" PML","pipe":" | ","alterations":" Chr t(15;17)","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Mylotarg (gemtuzumab ozogamicin) • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 05/04/2016","study_completion_date":" 05/04/2016","last_update_posted":"2023-01-10"},{"id":"a38ba7d6-a220-4bff-9bf0-90309625cd62","acronym":"APL0406","url":"https://clinicaltrials.gov/study/NCT00482833","created_at":"2021-03-29T12:16:38.586Z","updated_at":"2024-07-02T16:36:02.654Z","phase":"Phase 3","brief_title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","source_id_and_acronym":"NCT00482833 - APL0406","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idarubicin hydrochloride • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 276","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 10/17/2019","study_completion_date":" 10/17/2019","last_update_posted":"2022-10-11"},{"id":"74b84726-5dfa-4905-ad2e-aecfba9ada28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02200978","created_at":"2021-01-18T10:17:32.797Z","updated_at":"2024-07-02T16:36:10.731Z","phase":"Phase 4","brief_title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","source_id_and_acronym":"NCT02200978","lead_sponsor":"South China Children's Leukemia Group","biomarkers":" PML","pipe":" | ","alterations":" RARA positive","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RARA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-05-10"},{"id":"8a7bbd71-8642-4694-a50d-cc6f1326a302","acronym":"","url":"https://clinicaltrials.gov/study/NCT01404949","created_at":"2021-01-18T05:46:30.343Z","updated_at":"2024-07-02T16:36:20.058Z","phase":"Phase 2","brief_title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","source_id_and_acronym":"NCT01404949","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TERT • PML","pipe":"","alterations":" ","tags":["TERT • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-11-30"},{"id":"31e64661-e7cd-458f-9157-198adacd1c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT01296178","created_at":"2021-01-18T05:16:00.306Z","updated_at":"2024-07-02T16:36:32.987Z","phase":"","brief_title":"PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years","source_id_and_acronym":"NCT01296178","lead_sponsor":"PETHEMA Foundation","biomarkers":" PML","pipe":"","alterations":" ","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-03-23"},{"id":"3409c672-f11b-4c1d-9fa5-68b3f2b7ef28","acronym":"","url":"https://clinicaltrials.gov/study/NCT01064557","created_at":"2021-01-18T04:11:39.307Z","updated_at":"2024-07-02T16:36:40.036Z","phase":"","brief_title":"\"AIDA\" Protocol (LAP 0493)","source_id_and_acronym":"NCT01064557","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" PML","pipe":"","alterations":" ","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 1068","initiation":"Initiation: 10/01/1993","start_date":" 10/01/1993","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-10-14"},{"id":"ce98ee02-21d8-47cc-adbf-beb7c12bd1ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03760445","created_at":"2021-01-18T18:28:53.713Z","updated_at":"2024-07-02T16:36:51.542Z","phase":"Phase 1/2","brief_title":"HDM201 Added to CT in R/R or Newly Diagnosed AML","source_id_and_acronym":"NCT03760445","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride • siremadlin (HDM201) • Noxafil (posaconazole) • midazolam hydrochloride"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 06/13/2023","study_completion_date":" 06/13/2023","last_update_posted":"2020-01-09"},{"id":"ca1cce76-4da6-4fbf-bdfa-002e28a88250","acronym":"APL2012","url":"https://clinicaltrials.gov/study/NCT01987297","created_at":"2022-05-31T05:55:44.114Z","updated_at":"2024-07-02T16:36:56.825Z","phase":"Phase 4","brief_title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","source_id_and_acronym":"NCT01987297 - APL2012","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • idarubicin hydrochloride • arsenic trioxide"],"overall_status":"Unknown status","enrollment":" Enrollment 738","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2019-08-19"},{"id":"52fed3d4-413e-4097-86f8-0092fe2f7147","acronym":"","url":"https://clinicaltrials.gov/study/NCT00413166","created_at":"2021-01-18T01:27:04.006Z","updated_at":"2024-07-02T16:36:59.866Z","phase":"Phase 2","brief_title":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","source_id_and_acronym":"NCT00413166","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2019-05-07"},{"id":"ab864958-399d-451e-b668-5eba2ff86a0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352650","created_at":"2021-01-18T05:31:47.169Z","updated_at":"2024-07-02T16:37:09.315Z","phase":"Phase 1","brief_title":"Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01352650","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" RUNX1 • PML","pipe":"","alterations":" ","tags":["RUNX1 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/17/2011","start_date":" 06/17/2011","primary_txt":" Primary completion: 12/27/2016","primary_completion_date":" 12/27/2016","study_txt":" Completion: 12/27/2016","study_completion_date":" 12/27/2016","last_update_posted":"2018-07-02"},{"id":"ede587aa-8ffb-467a-ad41-58659b9802fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01435343","created_at":"2021-01-18T05:56:09.958Z","updated_at":"2024-07-02T16:37:23.126Z","phase":"Phase 1/2","brief_title":"Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia","source_id_and_acronym":"NCT01435343","lead_sponsor":"PETHEMA Foundation","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-04-25"},{"id":"78e41365-49e6-4d89-aeff-a6a011151354","acronym":"ICAML2015","url":"https://clinicaltrials.gov/study/NCT03023384","created_at":"2021-01-18T14:52:39.006Z","updated_at":"2024-07-02T16:37:26.001Z","phase":"","brief_title":"Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML","source_id_and_acronym":"NCT03023384 - ICAML2015","lead_sponsor":"International Consortium on Acute Leukemias","biomarkers":" PML","pipe":"","alterations":" ","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Unknown status","enrollment":" Enrollment 547","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2017-02-03"},{"id":"d6fec820-8601-4075-90da-c1c5961cb1a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01226303","created_at":"2021-01-18T04:55:38.686Z","updated_at":"2024-07-02T16:37:26.214Z","phase":"Phase 3","brief_title":"Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia","source_id_and_acronym":"NCT01226303","lead_sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","biomarkers":" NPM1 • RARA • PML","pipe":"","alterations":" ","tags":["NPM1 • RARA • PML"],"overall_status":"Unknown status","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-01-26"}]